New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
07:06 EDTAUXL, SNY, VVUSVIVUS announces avanafil clinical data presentation
VIVUS (VVUS) announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology Congress. STENDRA, or avanafil, is approved by the FDA in the U.S. for the treatment of erectile dysfunction. VIVUS has granted Auxilium Pharmaceuticals (AUXL) exclusive marketing rights to STENDRA in the U.S. and Canada. Auxilium is in the early stages of commercializing STENDRA in the U.S. SPEDRA is the trade name for avanafil in the European Union and is approved by the European Medicines Agency for the treatment of erectile dysfunction in the EU. VIVUS has granted an exclusive license to Sanofi (SNY) to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States including Russia.
News For VVUS;SNY;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
11:09 EDTSNYSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
March 3, 2015
11:46 EDTSNYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
11:25 EDTVVUSOrexigen surges after disclosing weight loss drug data, patent news
Shares of Orexigen (OREX) are surging in morning trading after the company disclosed the data from the 25% interim analysis of the LIGHT cardiovascular study when announcing a method of treatment patent was issued for its weight loss drug, Contrave. In the filing, the company disclosed that Contrave demonstrated a statistically significant benefit over placebo for cardiovascular events, including CV death. ANALYST OPINION: The new patent announced today extends protection for Contrave to 2034, analysts at Piper Jaffray stated. The firm thinks the new data could possibly drive a competitive advantage in the U.S. market for Contrave, and enhance probability of approvals outside the U.S. It kept an Overweight rating on Orexigen and raised its price target on the stock to $26 from $16. Meanwhile, Leerink noted the data show a statistically significant Contrave benefit in the intent-to-treat population on MACE, myocardial infarction, stroke, and cardiovascular death. The firm believes the results "present meaningful upside to expectations" and could have a positive impact on the Contrave launch if they are included on the drug's labels. Leerink reiterates an Outperform rating on Orexigen. OTHERS TO WATCH: Other companies that offer weight loss drugs that compete with Contrave include VIVUS (VVUS) and Arena Pharmaceuticals (ARNA). PRICE ACTION: In morning trading, Orexigen shares surged 44.5% to $8.37, VIVUS shares rose 8% to $2.99 and Arena slid 3.5% to $4.13.
March 2, 2015
08:53 EDTSNYNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
February 27, 2015
07:22 EDTSNYSanofi reports positive opinion from CHMP for Toujeo
Sanofi announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has issued a positive opinion recommending the approval of Toujeo, a next-generation basal insulin for the treatment of adults with type 1 and type 2 diabetes. Toujeo has demonstrated a more stable and a prolonged glycemic control that lasts beyond 24 hours compared with Lantus with low within-individual, within-day blood sugar variability. The European Commission is expected to make a final decision on granting marketing authorization for Toujeo in the EU in the coming months. Toujeo was approved by the FDA and is under review by other regulatory authorities around the world. Once approved, Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 insulin units, and it has a maximum single injection dose of 80 IU.
February 26, 2015
05:32 EDTSNYSanofi receives FDA approval of once-daily basal insulin Toujeo
Sanofi announced that the FDA approved Toujeo, a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2. The approval of Toujeo was based on FDA review of results from the EDITION clinical trial program, which was comprised of a series of international Phase III studies evaluating the efficacy and safety of Toujeo in more than 3,500 adults from broad and diverse diabetes populations.
February 25, 2015
20:05 EDTSNYSanofi receives FDA approval of once-daily basal insulin Toujeo
Subscribe for More Information
February 24, 2015
16:01 EDTVVUSVIVUS reports Q4 EPS (25c), consensus (25c)
Reports Q4 revenue $21.7M, consensus $20.01M.
February 20, 2015
07:08 EDTSNYAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:50 EDTSNYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
09:59 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
06:21 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
05:31 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use